CTOs on the Move

Ohr Pharmaceutical

www.ohrpharmaceutical.com

 
Ohr Pharmaceutical, Inc. (OHRP) is an ophthalmology research and development company. The company`s lead product, Squalamine (OHR-102), is currently being studied as an eye drop formulation in several company sponsored and investigator sponsored Phase II clinical trials for various back-of-the-eye diseases, including the wet form of age-related macular degeneration, retinal vein occlusion, diabetic macular edema, and proliferative diabetic retinopathy. In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform with several preclinical drug product candidates in development for glaucoma, steroid-induced glaucoma, ocular allergies, and protein drug delivery.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details
Irach Taraporewala
Chief Technology Officer Profile

Similar Companies

OrthoArizona

Enjoy the freedom of a pain-free, active lifestyle with help from our orthopedic specialists at OrthoArizona. Learn more today!

Coastal Medical

Coastal Medical, Inc. is Rhode Islands largest, physician owned and physician governed Primary Care practice, serving patients in RI and southeastern Massachusetts.

Reliance Health

Reliance Health is a non-profit community mental health center focused on enhancing health through mental wellness.

CNS Healthcare

Providing mental health and substance use disorder services for children, youth, and adults. No insurance needed. #EndStigma

Impax Laboratories

Impax Laboratories is a technology-based specialty pharmaceutical company utilizing our core competency in drug delivery and formulation expertise. We have a balanced business model consisting of a successful generic business targeting high-value solid oral and alternative dosage form Abbreviated New Drug Applications (ANDA), and a branded business currently focused on internally developing Central Nervous System (CNS) products where we can deliver meaningful patient benefits and develop strong intellectual property positions.